Vera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Update

Vera Therapeutics, Inc. (NASDAQ:VERA) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 242,700 shares, an increase of 185.2% from the December 15th total of 85,100 shares. Approximately 3.3% of the company’s shares are short sold. Based on an average trading volume of 58,400 shares, the short-interest ratio is currently 4.2 days.

Shares of VERA stock opened at $19.99 on Friday. The firm’s 50-day simple moving average is $24.93 and its 200-day simple moving average is $20.17. Vera Therapeutics has a 1-year low of $11.30 and a 1-year high of $37.11.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Wednesday, November 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.33. Analysts forecast that Vera Therapeutics will post -2.01 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio acquired a new stake in Vera Therapeutics during the 3rd quarter worth approximately $27,000. California State Teachers Retirement System acquired a new stake in Vera Therapeutics in the third quarter valued at approximately $66,000. American International Group Inc. acquired a new stake in Vera Therapeutics in the third quarter valued at approximately $67,000. Deutsche Bank AG acquired a new stake in shares of Vera Therapeutics during the third quarter worth approximately $71,000. Finally, Bank of America Corp DE bought a new position in Vera Therapeutics during the second quarter worth $82,000. 65.72% of the stock is owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research lowered shares of Vera Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 29th.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.

Read More: What is quantitative easing?

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with's FREE daily email newsletter.